Toggle navigation
Home
Search
Services
Blog
Contact
About
TB Center Grant
Temesgen, Zelalem
Mayo Clinic, Rochester, Rochester, MN, United States
Search 11 grants from Zelalem Temesgen
Search grants from Mayo Clinic, Rochester
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Retinoic acid signaling: a novel factor for addiction-related behavior
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
Discovery and Characterization of Methylation Markers
Functionally probing hSGLT2 in diabetes treatment and glucose homeostasis
Factors in Drug Dependence
Recently added grants:
Roles of Telomeric Oxidative DNA Lesions in Telomere Length Regulation
Cancer Epigenetics: A novel PRC2 Dysregulation Mechanism in Multiple Myeloma
A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genes
Lung Cancer in Never-smokers: Role of Estrogen and its Metabolites
Identification of USP13 as a therapeutic target for ovarian cancer
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Center for HIV, Viral Hepatitis, STDS and Tb Prevention (NCHHSTP)
Type
Cooperative Agreement for Tuberculosis Control (U52)
Project #
1U52PS004096-01
Application #
8536452
Study Section
Special Emphasis Panel (ZPS1-SRC (99))
Project Start
2013-01-01
Project End
2017-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
1
Fiscal Year
2013
Total Cost
$1,072,947
Indirect Cost
$79,480
Institution
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Related projects
NIH 2015
U52 PS
TB Center Grant
Temesgen, Zelalem / Mayo Clinic, Rochester
NIH 2014
U52 PS
TB Center Grant
Temesgen, Zelalem / Mayo Clinic, Rochester
$536,474
NIH 2013
U52 PS
TB Center Grant
Temesgen, Zelalem / Mayo Clinic, Rochester
$1,072,947
Comments
Be the first to comment on Zelalem Temesgen's grant